← Leaderboards
Julia Davydova
University Of Minnesota
$3,953,014
Attributed
$4,826,656
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $826K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,826,656 · 3
By mechanism
R01$4,826,656 · 3
Top collaborators
- Masato Yamamoto5 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Masato Yamamoto$9,316,402
- George V Aslanidi$2,567,167
Others in their field
Top investigators on “Tissues”
- David Heimbrook · Leidos Biomedical Research, Inc.$346,311,904
- Lawrence Corey · Fred Hutchinson Cancer Center$230,011,824
- Larry Arthur$159,140,370
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Judith S. Currier · University Of California Los Angeles$138,805,403
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$138,805,403
Research focus
TissuesOperative Surgical ProceduresNeoplasm MetastasisSuccessUnresectableCancer CellExcisionDiagnosisMediatingPhase I Clinical TrialsTumorImmunityOncolysisOncolyticAdenovirusesCessation Of LifeDesignCancer EtiologyEffective TherapyImmunocompetentMalignant Neoplasm Of PancreasHamstersCombined Modality TherapyNovel Therapeutics
Grant awards (13)
Advancing Systematic Delivery of Oncolytic Adenovirus for Pancreatic Cancer$511,669
R01 · FY2025 · CA · contact PI
Advancing Systematic Delivery of Oncolytic Adenovirus for Pancreatic Cancer$478,754
R01 · FY2024 · CA · contact PI
Advancing Systematic Delivery of Oncolytic Adenovirus for Pancreatic Cancer$480,793
R01 · FY2023 · CA · contact PI
Combination therapy with IFN expressing oncolytic adenovirus for pancreatic cancer$345,230
R01 · FY2023 · CA
Combination therapy with IFN expressing oncolytic adenovirus for pancreatic cancer$345,230
R01 · FY2022 · CA
Combination therapy with IFN expressing oncolytic adenovirus for pancreatic cancer$352,275
R01 · FY2021 · CA
Combination therapy with IFN expressing oncolytic adenovirus for pancreatic cancer$352,275
R01 · FY2020 · CA
Combination therapy with IFN expressing oncolytic adenovirus for pancreatic cancer$352,275
R01 · FY2019 · CA
Novel Theranostics for Pancreatic Cancer$319,031
R01 · FY2018 · CA · contact PI
Novel Theranostics for Pancreatic Cancer$319,031
R01 · FY2017 · CA · contact PI
Novel Theranostics for Pancreatic Cancer$319,031
R01 · FY2016 · CA · contact PI
Novel Theranostics for Pancreatic Cancer$319,031
R01 · FY2015 · CA · contact PI
Novel Theranostics for Pancreatic Cancer$332,031
R01 · FY2014 · CA · contact PI